Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.42 |
| ▸ | CA2 | P00918 | 2/20 | 0.42 |
| ▸ | CA7 | P43166 | 2/20 | 0.42 |
| ▸ | CA9 | Q16790 | 2/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.42 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | ACHE | P22303 | 1/20 | 0.36 |
| ▸ | IDO1 | P14902 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.34 |
| ▸ | MAPT | P10636 | 3/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.33 |
| ▸ | AGXT | P21549 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | THRB | P10828 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16958737 | 0.85 | CA12 (0.40) | CA1CA2CA7CA9CA12 | |
| SCHEMBL15063892 | 0.84 | ESR2 (0.44) | CA1CA2CA7CA9CA12 | |
| SCHEMBL6846298 | 0.82 | HRH2 (0.39) | CA1CA2CA7CA9CA12 | |
| SCHEMBL7772435 | 0.81 | NQO1 (0.52) | CA1CA2CA7CA9CA12 | |
| SCHEMBL3924093 | 0.81 | TAAR1 (0.41) | CA1CA2CA7CA9CA12 | |
| SCHEMBL21708160 | 0.80 | NQO1 (0.32) | — | |
| SCHEMBL18705940 | 0.79 | SLC6A4 (0.42) | CA1CA2CA7CA9CA12 | |
| SCHEMBL28117570 | 0.79 | CASP3 (0.41) | MAPK1THRBALDH1A1CYP3A4 | |
| SCHEMBL21708116 | 0.79 | KDM4E (0.38) | TDP1MAPK1MAPTL3MBTL1KDM4E | |
| SCHEMBL18705795 | 0.78 | MEN1 (0.37) | CA1CA2CA7CA9CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3237385-B1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | US HEALTH (US) | 2021-11-24 | — | — | EP | claimed |
| CN-107428690-B | Mutant IDH1 inhibitors useful for the treatment of cancer | 美国政府健康及人类服务部 | 2021-04-13 | — | — | CN | claimed |
| US-10703746-B2 | Mutant IDH1 inhibitors useful for treating cancer | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-07-07 | — | — | US | claimed |
| US-20190071434-A1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | THE USA AS REPRESENTED BY THE SEC DEP OF HEALTH AND HUMAN SERVICES (US) | 2019-03-07 | — | — | US | claimed |
| EP-3237385-A1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | The United States of America, as represented by The Secretary, Department of Health and Human Services (US) | 2017-11-01 | — | — | EP | claimed |
| WO-2016106331-A1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | THE UNITED STATES OF AMERICA (US) | 2016-06-30 | — | — | WO | claimed |
| EP-1814847-B1 | NOVEL METHOD FOR PREPARING 3-[5'-(3,4-BIS-HYDROXYMETHYL-BENZYLOXY)-2'- ETHYL-2-PROPYL-BIPHENYL-4-YL]-PENTA-3-OL | GALDERMA RES & DEV (FR) | 2011-01-12 | — | — | EP | claimed |
| EP-1814847-A1 | NOVEL METHOD FOR PREPARING 3-[5'-(3,4-BIS-HYDROXYMETHYL-BENZYLOXY)-2'- ETHYL-2-PROPYL-BIPHENYL-4-YL]-PENTA-3-OL | Galderma Research & Development (FR) | 2007-08-08 | — | — | EP | claimed |
| WO-2006053985-A1 | NOVEL METHOD FOR PREPARING 3-[5'-(3,4-BIS-HYDROXYMETHYL-BENZYLOXY)-2'- ETHYL-2-PROPYL-BIPHENYL-4-YL]-PENTA-3-OL | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-05-26 | — | — | WO | claimed |
| EP-0986560-B1 | PYRROLO 2,1,5-CD]INDOLIZINE DERIVATIVES USEFUL IN THE PREVENTION OR TREATMENT OF ESTROGEN RELATED DISEASES OR SYNDROMES | KAROBIO AB (SE) | 2004-03-24 | — | — | EP | claimed |
| EP-3237385-B1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | US HEALTH (US) | 2021-11-24 | — | — | EP | disclosed |
| US-11000038-B2 | Pyridone compounds and agricultural and horticultural fungicides containing the same as active ingredients | MITSUI CHEMICALS AGRO, INC. (JP) | 2021-05-11 | — | — | US | disclosed |
| CN-107428690-B | Mutant IDH1 inhibitors useful for the treatment of cancer | 美国政府健康及人类服务部 | 2021-04-13 | — | — | CN | disclosed |
| US-10703746-B2 | Mutant IDH1 inhibitors useful for treating cancer | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2020-07-07 | — | — | US | disclosed |
| US-20200196600-A1 | PYRIDONE COMPOUNDS AND AGRICULTURAL AND HORTICULTURAL FUNGICIDES CONTAINING THE SAME AS ACTIVE INGREDIENTS | MITSUI CHEMICALS AGRO, INC. (JP) | 2020-06-25 | — | — | US | disclosed |
| US-6184245-B1 | Cyclic ketone derivatives and their medical applications | TORAY INDUSTRIES INC. (JP) | 2001-02-06 | — | — | US | disclosed |
| US-6100292-A | Ketone derivatives and their medical applications | TORAY INDUSTRIES, INC. (JP) | 2000-08-08 | — | — | US | disclosed |
| WO-2000017157-A1 | OPTICALLY ACTIVE SUBSTITUTED N-ARYL-O-ARYLOXYALKYL-CARBAMATES | BAYER AKTIENGESELLSCHAFT (DE) | 2000-03-30 | — | — | WO | disclosed |
| EP-0980867-A1 | KETONE DERIVATIVES AND MEDICINAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 2000-02-23 | — | — | EP | disclosed |
| EP-0962456-A1 | CYCLIC KETONE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | TORAY INDUSTRIES, INC. (JP) | 1999-12-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200196600-A1 | PYRIDONE COMPOUNDS AND AGRICULTURAL AND HORTICULTURAL FUNGICIDES CONTAINING THE SAME AS ACTIVE INGREDIENTS | PNPO, PDXK, PLPBP | CA1 4274/4885CA2 3202/4885CA7 3722/4885 |
| US-20190071434-A1 | MUTANT IDH1 INHIBITORS USEFUL FOR TREATING CANCER | IDH1, IDH3B, IDH3A | CA1 1401/4885CA2 847/4885CA7 996/4885 |
| US-11000038-B2 | Pyridone compounds and agricultural and horticultural fungicides containing the same as active ingredients | PNPO, PDXK, PLPBP | CA1 4274/4885CA2 3202/4885CA7 3722/4885 |
| US-10703746-B2 | Mutant IDH1 inhibitors useful for treating cancer | IDH1, IDH3B, IDH3A | CA1 1401/4885CA2 847/4885CA7 996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.